Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 119-143 peptide is a 25-amino acid peptide fragment derived from the cancer-testis antigen NY-ESO-1 (residues 119-143). It functions as a promiscuous MHC class II-restricted T-helper epitope, capable of binding to multiple HLA-DR alleles, including HLA-DRB1*0401, DRB1*0101, and others. By presenting these epitopes to CD4+ T cells, the peptide stimulates both Th1- and Th2-type immune responses, which are critical for coordinating cellular and humoral anti-tumor immunity. This peptide has been investigated as a component of therapeutic cancer vaccines, particularly for melanoma and other NY-ESO-1-expressing malignancies, to enhance the recognition and destruction of tumor cells by the immune system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NY-ESO-1 119-143 peptide.